

Amendments to the Claims:

This Listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A pharmaceutical composition, comprising:
a peptide or pharmaceutically acceptable salt thereof, whereby the peptide or
pharmaceutically acceptable salt contains an amino acid sequence
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES (LL-37) (SEQ ID NO: 1); and a
carrier.

Claim 2 (currently amended): A method of increasing angiogenesis, comprising administering a
pharmaceutical composition containing a peptide or pharmaceutically acceptable salt thereof
containing the amino acid sequence LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES
(LL-37) (SEQ ID NO: 1).

Claim 3 (currently amended): A method of preventing or treating disease, comprising
administering a therapeutically effective dose of a pharmaceutical composition containing a
peptide or pharmaceutically acceptable salt thereof, whereby the peptide or pharmaceutically
acceptable salt contains an amino acid sequence
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES (LL-37) (SEQ ID NO: 1).

Claim 4 (original): The method of claim 3, whereby the disease is caused by or results in reduced
blood flow, reduced level of angiogenesis, or reduced level of arteriogenesis.

Claim 5 (original): The method of claim 3, whereby the disease is atherosclerosis, coronary heart
disease, stroke, arterial occlusive disease, or an ulcer.

Claim 6 (currently amended): A method of treating a wound, comprising administering a therapeutically effective dose of a pharmaceutical composition containing a peptide or pharmaceutically acceptable salt thereof, whereby the peptide or pharmaceutically acceptable salt contains an amino acid sequence LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLPRTES (LL-37) (SEQ ID NO: 1).

Claim 7 (original): The method of claim 6, whereby the wound is an infected wound.

Claim 8 (original): The method of claim 6, whereby the wound is a non-infected wound.

Claim 9 (original): A method of decreasing the level of angiogenesis, comprising administering an agent that inhibits the biological activity of LL-37.

Claim 10 (original): The method of claim 9, whereby the agent performs an action selected from the group consisting of blocking an interaction between LL-37 and an LL-37 receptor molecule, blocking an intracellular signal, blocking an intracellular signal cascade mediated by an LL-37 specific receptor, and blocking the growth of arteries.

Claim 11 (original): The method of claim 10, whereby the LL-37 receptor molecule is FPRL1-receptor.

Claim 12 (original): The method of claim 10, whereby the agent which blocks an interaction of LL-37 is an anti-LL-37 antibody, an anti-LL37-receptor antibody; a non-stimulatory form of LL-37, or a soluble form of a LL37-receptor.

Claim 13 (original): The method of claim 9 whereby the agent is selected from the group consisting of a(n) antibody, polypeptide, peptide, nucleic acid, small organic compound, ligand, hormone, peptide nucleic acid, and peptidomimetic.

Claim 14 (original): A method of decreasing tumor size, comprising administering a therapeutically effective dose of an agent that inhibits the biological activity of LL-37.

Claim 15 (original): The method of claim 14, whereby the LL-37 receptor molecule is FPRL1-receptor.

Claim 16 (original): The method of claim 14, whereby the agent which blocks an interaction of LL-37 is selected from the group consisting of anti-LL-37 antibody, anti-LL37-receptor antibody; non-stimulatory form of LL-37, and a soluble form of a LL37-receptor.

Claim 17 (original): The method of claim 14 whereby the agent is selected from the group consisting of a(n) antibody, polypeptide, peptide, nucleic acid, small organic compound, ligand, hormone, peptide nucleic acid, and peptidomimetic.

Claim 18 (original): The method of claim 14, whereby the tumor is selected form the group consisting of carcinoma or sarcoma including cancer of the bile duct, brain, breast, colon, stomach, male and female reproductive organs, lung and airways, skin, gallbladder, liver, nasopharynx, nerve cells, kidney, prostate, glands and Kaposi's sarcoma.

Claim 19 (original): A method of altering the specificity of LL-37 contained in a compound, comprising:

identifying binding sites of LL-37 and an LL-37 specific receptor;
model the binding site of LL-37 and the receptor using molecular modeling; and
modifying the compound to increase the specificity found in the modeling step.

Claim 20 (original): The method of claim 19, whereby the identifying step is performed by site directed mutagenesis or chimeric protein studies.